Aptose Biosciences (TSE:APS) Shares Pass Above Fifty Day Moving Average – Time to Sell?

Shares of Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of C$2.21 and traded as high as C$2.25. Aptose Biosciences shares last traded at C$2.25, with a volume of 3,066 shares trading hands.

Aptose Biosciences Stock Performance

The company has a debt-to-equity ratio of -97.77, a current ratio of 0.53 and a quick ratio of 5.41. The stock has a market cap of C$6.10 million, a PE ratio of 3.46 and a beta of -1.19. The business has a 50 day moving average price of C$2.22 and a two-hundred day moving average price of C$2.06.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last announced its quarterly earnings results on Tuesday, March 31st. The biotechnology company reported C($4.07) earnings per share for the quarter. As a group, equities research analysts forecast that Aptose Biosciences Inc. will post -0.59 EPS for the current fiscal year.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.